Moderna, Inc. (MRNA) stock experienced a significant pre-market decline of 5.1% following an analyst price target revision. The pre-market plunge occurred on Thursday, March 6th, 2025.
According to reports, Berenberg analysts adjusted their price target for Moderna down to $30 from the previous target of $33. The analysts maintained their "Hold" rating on the stock, reflecting a cautious outlook.
The downward revision of the price target by Berenberg analysts appears to have contributed to the pre-market sell-off in Moderna's shares. Investors reacted negatively to the reduced price expectations, as reflected in the stock's 5.1% drop during the pre-market trading session.